OVERVIEW

Optimizing Cancer Screening With MCED Technologies: From Science to Practical Application - Module 2: Clinical Evidence for MCED Testing is organized by i3 Health.

Dates Available:
August 20, 2024 - August 19, 2025

Description:
Discover the future of cancer screening with our exclusive CME podcast series, Optimizing Cancer Screening With MCED Technologies: From Science to Practical Application.

Join Dr. Charles Vega in Module 2 of our CME podcast as he delves into the cutting-edge world of multicancer early detection (MCED) tests. With nearly 2 million new cancer cases expected in 2024, the role of early detection has never been more critical. Dr. Vega will unpack the latest clinical trial data on MCED tests for gynecologic, gastrointestinal, and hematologic cancers, exploring their potential to revolutionize cancer screening and improve patient outcomes.

Statement Of Need:
Approximately 2 million new cancer cases are expected in the United States in 2024, with an anticipated 611,720 deaths (ACS, 2024). Screening is associated with earlier stage at diagnosis and improved outcomes (Kim et al, 2011; Plumb et al, 2016). Multicancer early detection (MCED) is an emerging form of blood-based testing that utilizes cancer biomarkers in the blood to screen for multiple cancers simultaneously (ACS, 2024). Currently, numerous clinical trials are investigating the sensitivity and specificity of MCED tests, their performance in different populations, their impact on patients, and their implementation into the clinical setting (Lennon et al, 2020; Rubinstein et al, 2024; Gao et al, 2023; Schrag et al, 2022; Lennon et al, 2023; Nicholson et al, 2023). In Module 2 of this activity, Dr. Charles Vega, Clinical Professor of Family Medicine in the School of Medicine at the University of California, Irvine, will discuss the latest clinical trial data of MCED tests in gynecologic, gastrointestinal, and hematologic cancers and the insights into the future of MCED that these trials aim to provide.

Learning Objectives:
Upon completion of this activity, participants should be able to:

Differentiate MCED tests from other blood-based screening tests
Explain how MCED testing complements existing screening and diagnostic methods in gastrointestinal, gynecologic, and hematologic cancers
Assess current and emerging data supporting the use of MCED tests in clinical practice
Discuss tactics to promote the widespread adoption of cancer screening in the community
Apply practical tools and strategies for integrating the latest cancer screening technologies into the clinical workflow

ACCREDITATION & CREDITS

Jointly Accredited Provider:
In support of improving patient care, i3 Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians:
i3 Health designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

By providing this information, participants are agreeing to allow i3 Health to share this information with the ACCME.

Physician Assistants/Associates:
i3 Health has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credits. Approval is valid until 8/19/25. PAs should only claim credit commensurate with the extent of their participation.

Nurse Practitioners:
The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Individuals are responsible for checking with the AANPCP for further guidelines.

0.5 AMA PRA Category 1 Credit™

0.5 MOC

FACULTY

Charles Vega

MDFamily Medicine

TARGET AUDIENCE

PhysicianPhysician AssistantObstetrics and Gynecology PhysiciansObstetriciansNurse PractitionersGynaecologistMedical OncologistsOncological Nursing StaffGynecological Oncologists